Literature DB >> 17130298

Vancomycin-intermediate Staphylococcus aureus strains have impaired acetate catabolism: implications for polysaccharide intercellular adhesin synthesis and autolysis.

Jennifer L Nelson1, Kelly C Rice, Sean R Slater, Paige M Fox, Gordon L Archer, Kenneth W Bayles, Paul D Fey, Barry N Kreiswirth, Greg A Somerville.   

Abstract

The most common mechanism by which Staphylococcus aureus gains resistance to vancomycin is by adapting its physiology and metabolism to permit growth in the presence of vancomycin. Several studies have examined the adaptive changes occurring during the transition to vancomycin-intermediate resistance, leading to a model of vancomycin resistance in which decreased cell wall turnover and autolysis result in increased cell wall thickness and resistance to vancomycin. In the present study, we identified metabolic changes common to vancomycin-intermediate S. aureus (VISA) strains by assessing the metabolic and growth characteristics of two VISA strains (vancomycin MICs of 8 microg/ml) and two isogenic derivative strains with vancomycin MICs of 32 microg/ml. Interestingly, we observed the parental strains had impaired catabolism of nonpreferred carbon sources (i.e., acetate), and this impairment became more pronounced as vancomycin resistance increased. To determine if acetate catabolism impairment is common to VISA strains, we assessed the ability of VISA and vancomycin-sensitive S. aureus (VSSA) clinical isolates to catabolize acetate. As expected, a significantly greater percentage of VISA strains (71%) had impaired acetate catabolism relative to VSSA (8%). This is an important observation because staphylococcal acetate catabolism is implicated in growth yield and antibiotic tolerance and in regulating cell death and polysaccharide intercellular adhesin synthesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17130298      PMCID: PMC1797750          DOI: 10.1128/AAC.01057-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  37 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Vancomycin-resistant Staphylococcus aureus--Pennsylvania, 2002.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2002-10-11       Impact factor: 17.586

3.  In vitro serial passage of Staphylococcus aureus: changes in physiology, virulence factor production, and agr nucleotide sequence.

Authors:  Greg A Somerville; Stephen B Beres; J Ross Fitzgerald; Frank R DeLeo; Robert L Cole; Jessica S Hoff; James M Musser
Journal:  J Bacteriol       Date:  2002-03       Impact factor: 3.490

4.  Acetic acid induces expression of the Staphylococcus aureus cidABC and lrgAB murein hydrolase regulator operons.

Authors:  Kelly C Rice; Jeremy B Nelson; Toni G Patton; Soo-Jin Yang; Kenneth W Bayles
Journal:  J Bacteriol       Date:  2005-02       Impact factor: 3.490

5.  Inactivated pbp4 in highly glycopeptide-resistant laboratory mutants of Staphylococcus aureus.

Authors:  K Sieradzki; M G Pinho; A Tomasz
Journal:  J Biol Chem       Date:  1999-07-02       Impact factor: 5.157

6.  Biofilm formation, icaADBC transcription, and polysaccharide intercellular adhesin synthesis by staphylococci in a device-related infection model.

Authors:  Ursula Fluckiger; Martina Ulrich; Andrea Steinhuber; Gerd Döring; Dietrich Mack; Regine Landmann; Christiane Goerke; Christiane Wolz
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

7.  Staphylococcus aureus aconitase inactivation unexpectedly inhibits post-exponential-phase growth and enhances stationary-phase survival.

Authors:  Greg A Somerville; Michael S Chaussee; Carrie I Morgan; J Ross Fitzgerald; David W Dorward; Lawrence J Reitzer; James M Musser
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

8.  Staphylococcus aureus resistant to vancomycin--United States, 2002.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2002-07-05       Impact factor: 17.586

9.  Morphological and genetic differences in two isogenic Staphylococcus aureus strains with decreased susceptibilities to vancomycin.

Authors:  Andrea Reipert; Kerstin Ehlert; Thomas Kast; Gabriele Bierbaum
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

10.  Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus.

Authors:  Longzhu Cui; Xiaoxue Ma; Katsuhiro Sato; Keiko Okuma; Fred C Tenover; Elsa M Mamizuka; Curtis G Gemmell; Mi-Na Kim; Marie-Cecile Ploy; N El-Solh; Vivian Ferraz; Keiichi Hiramatsu
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

View more
  20 in total

Review 1.  At the crossroads of bacterial metabolism and virulence factor synthesis in Staphylococci.

Authors:  Greg A Somerville; Richard A Proctor
Journal:  Microbiol Mol Biol Rev       Date:  2009-06       Impact factor: 11.056

2.  Staphylococcus aureus metabolic adaptations during the transition from a daptomycin susceptibility phenotype to a daptomycin nonsusceptibility phenotype.

Authors:  Rosmarie Gaupp; Shulei Lei; Joseph M Reed; Henrik Peisker; Susan Boyle-Vavra; Arnold S Bayer; Markus Bischoff; Mathias Herrmann; Robert S Daum; Robert Powers; Greg A Somerville
Journal:  Antimicrob Agents Chemother       Date:  2015-05-11       Impact factor: 5.191

3.  Role of the msaABCR Operon in Cell Wall Biosynthesis, Autolysis, Integrity, and Antibiotic Resistance in Staphylococcus aureus.

Authors:  Bibek G C; Gyan S Sahukhal; Mohamed O Elasri
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

Review 4.  Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.

Authors:  Benjamin P Howden; John K Davies; Paul D R Johnson; Timothy P Stinear; M Lindsay Grayson
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

5.  Metabolic Mitigation of Staphylococcus aureus Vancomycin Intermediate-Level Susceptibility.

Authors:  Stewart G Gardner; Darrell D Marshall; Robert S Daum; Robert Powers; Greg A Somerville
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

Review 6.  Molecular control of bacterial death and lysis.

Authors:  Kelly C Rice; Kenneth W Bayles
Journal:  Microbiol Mol Biol Rev       Date:  2008-03       Impact factor: 11.056

7.  Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus.

Authors:  Michael Meehl; Silvia Herbert; Friedrich Götz; Ambrose Cheung
Journal:  Antimicrob Agents Chemother       Date:  2007-05-14       Impact factor: 5.191

8.  Molecular characterization of α-amylase from Staphylococcus aureus.

Authors:  Hanumanthu Prasanna Lakshmi; Uppu Venkateswara Prasad; Sthanikam Yeswanth; Vimjam Swarupa; Osuru Hari Prasad; Mangamoori Lakshmi Narasu; Potukuchi Venkata Gurunadha Krishna Sarma
Journal:  Bioinformation       Date:  2013-03-19

9.  Production of capsular polysaccharide does not influence Staphylococcus aureus vancomycin susceptibility.

Authors:  Andrea Jansen; Christiane Szekat; Wiebke Schröder; Christiane Wolz; Christiane Goerke; Jean C Lee; Michael Türck; Gabriele Bierbaum
Journal:  BMC Microbiol       Date:  2013-03-22       Impact factor: 3.605

10.  Comparative proteomics-based identification of genes associated with glycopeptide resistance in clinically derived heterogeneous vancomycin-intermediate Staphylococcus aureus strains.

Authors:  Hongbin Chen; Yali Liu; Chunjiang Zhao; Di Xiao; Jianzhong Zhang; Feifei Zhang; Minjun Chen; Hui Wang
Journal:  PLoS One       Date:  2013-06-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.